REAL-TIMI 63B is a Phase 2b randomized, blinded, placebo controlled study to evaluate the efficacy, safety, PK/pharmacodynamic, and immunogenicity of repeat doses of MEDI6012 in adult subjects presenting with acute STEMI (ST segment elevation myocardial infarction).
MAIN RESULTS:
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B
Circulation. 2022 Sep 20;146(12):907-916.
PRESENTATIONS
Preliminary Results – Cardioprotection and Plaque Regression with MEDI6012 in Acute ST Elevation Myocardial Infarction – Primary Results of the Phase 2B REAL-TIMI 63B Randomized Clinical Trial (Bonaca, ACC 2021)
Cardiometabolic Risk Factors and Non-Culprit Plaque Characteristics in Patients with STEMI in REAL-TIMI 63B (Abdelrahman, AHA 2023)